85 related articles for article (PubMed ID: 9622544)
1. Arylpiperazines with serotonin-3 antagonist activity: a comparative molecular field analysis.
Morreale A; Gálvez-Ruano E; Iriepa-Canalda I; Boyd DB
J Med Chem; 1998 Jun; 41(12):2029-39. PubMed ID: 9622544
[TBL] [Abstract][Full Text] [Related]
2. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors.
Cappelli A; Anzini M; Vomero S; Canullo L; Mennuni L; Makovec F; Doucet E; Hamon M; Menziani MC; De Benedetti PG; Bruni G; Romeo MR; Giorgi G; Donati A
J Med Chem; 1999 May; 42(9):1556-75. PubMed ID: 10229626
[TBL] [Abstract][Full Text] [Related]
3. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
4. Binding of arylpiperazines, (aryloxy)propanolamines, and tetrahydropyridylindoles to the 5-HT1A receptor: contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-affinity relationship models.
Gaillard P; Carrupt PA; Testa B; Schambel P
J Med Chem; 1996 Jan; 39(1):126-34. PubMed ID: 8568799
[TBL] [Abstract][Full Text] [Related]
5. CoMFA and CoMSIA 3D QSAR analysis on N1-arylsulfonylindole compounds as 5-HT6 antagonists.
Doddareddy MR; Cho YS; Koh HY; Pae AN
Bioorg Med Chem; 2004 Aug; 12(15):3977-85. PubMed ID: 15246074
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships for the binding of arylpiperazines and arylbiguanides at 5-HT3 serotonin receptors.
Dukat M; Abdel-Rahman AA; Ismaiel AM; Ingher S; Teitler M; Gyermek L; Glennon RA
J Med Chem; 1996 Sep; 39(20):4017-26. PubMed ID: 8831767
[TBL] [Abstract][Full Text] [Related]
7. Structure-based 3D-QSAR studies on heteroarylpiperazine derivatives as 5-HT3 receptor antagonists.
Zhou YJ; Zhu LP; Tang Y; Ye DY
Eur J Med Chem; 2007 Jul; 42(7):977-84. PubMed ID: 17331624
[TBL] [Abstract][Full Text] [Related]
8. A comparative molecular field analysis (CoMFA) study using semiempirical, density functional, ab initio methods and pharmacophore derivation using DISCOtech on sigma 1 ligands.
Jung D; Floyd J; Gund TM
J Comput Chem; 2004 Aug; 25(11):1385-99. PubMed ID: 15185333
[TBL] [Abstract][Full Text] [Related]
9. [3D QSAR analysis of novel 5-HT1A receptor ligands].
Borosy AP
Acta Pharm Hung; 1998 Mar; 68(2):71-8. PubMed ID: 9592931
[TBL] [Abstract][Full Text] [Related]
10. 3D-QSAR comparative molecular field analysis on delta opioid receptor agonist SNC80 and its analogs.
Peng Y; Keenan SM; Zhang Q; Welsh WJ
J Mol Graph Model; 2005 Sep; 24(1):25-33. PubMed ID: 15950508
[TBL] [Abstract][Full Text] [Related]
11. Modification of the structure of 4, 6-disubstituted 2-(4-alkyl-1-piperazinyl)pyridines: synthesis and their 5-HT2A receptor activity.
Paluchowska MH; Bojarski AJ; Bugno R; Charakchieva-Minol S; Wesołowska A
Arch Pharm (Weinheim); 2003 Apr; 336(2):104-10. PubMed ID: 12761763
[TBL] [Abstract][Full Text] [Related]
12. Comparative molecular field analysis of a series of paclitaxel analogues.
Zhu Q; Guo Z; Huang N; Wang M; Chu F
J Med Chem; 1997 Dec; 40(26):4319-28. PubMed ID: 9435901
[TBL] [Abstract][Full Text] [Related]
13. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
[TBL] [Abstract][Full Text] [Related]
14. Melatonin receptor ligands: synthesis of new melatonin derivatives and comprehensive comparative molecular field analysis (CoMFA) study.
Mor M; Rivara S; Silva C; Bordi F; Plazzi PV; Spadoni G; Diamantini G; Balsamini C; Tarzia G; Fraschini F; Lucini V; Nonno R; Stankov BM
J Med Chem; 1998 Sep; 41(20):3831-44. PubMed ID: 9748358
[TBL] [Abstract][Full Text] [Related]
15. New 4-[omega-(diarylmethylamino)alkyl]- and 4-[omega-(diarylmethoxy)alkyl]-1-arylpiperazines as selective 5-HT1A/5-HT2A receptor ligands with differentiated in vivo activity.
Paluchowska MH; Charakchieva-Minol S; Tatarczyńska E; Kłodzińska A; Stachowicz K; Chojnacka-Wójcik E
Pol J Pharmacol; 2004; 56(6):743-54. PubMed ID: 15662087
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, 5-HT1A and 5-HT2A receptor activity of new 1-phenylpiperazinylpropyl derivatives with arylalkyl substituents in position 7 of purine-2,6-dione.
Chloń G; Pawłowski M; Duszyńska B; Szaro A; Tatarczńska E; Kłodzińska AL; Chojnacka-Wójcik E
Pol J Pharmacol; 2001; 53(4):359-68. PubMed ID: 11990082
[TBL] [Abstract][Full Text] [Related]
17. Application of validated QSAR models of D1 dopaminergic antagonists for database mining.
Oloff S; Mailman RB; Tropsha A
J Med Chem; 2005 Nov; 48(23):7322-32. PubMed ID: 16279792
[TBL] [Abstract][Full Text] [Related]
18. Effect of linking bridge modifications on the 5-HT1A receptor activity of some 4-(omega-benzotriazol-1-yl)alkyl-1-(2-methoxy-phenyl)piperazines.
Paluchowska MH; Kłodzińska A; Tatarczyńska E; Szaro A; Chojnacka-Wójcik E
Pol J Pharmacol; 1998; 50(4-5):341-7. PubMed ID: 10091719
[TBL] [Abstract][Full Text] [Related]
19. Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel.
Brown ML; Zha CC; Van Dyke CC; Brown GB; Brouillette WJ
J Med Chem; 1999 May; 42(9):1537-45. PubMed ID: 10229624
[TBL] [Abstract][Full Text] [Related]
20. Homology modeling of the serotonin 5-HT1A receptor using automated docking of bioactive compounds with defined geometry.
Nowak M; Kołaczkowski M; Pawłowski M; Bojarski AJ
J Med Chem; 2006 Jan; 49(1):205-14. PubMed ID: 16392805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
